ArticleJournal of clinical laboratory analysis2026
Effects of Spectral Interfering Substances on Light Transmission Platelet Aggregation Using Infrared Based Aggregometer.
Article in Journal of clinical laboratory analysis, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
aimThis study aims to investigate the nature and extent of hemolyzed, icteric, or lipemic (HIL) interference on platelet aggregation (PA) using the TA-8 V aggregometer (Diagnostica Stago, Asnière sur Seine) equipped with a near infrared light source outside the typical absorbance range of HIL.
methodsPlatelet-Rich-Plasma (PRP) samples were spiked with substances mimicking HIL interference: red blood cell hemolysate (RBCH; 0.3-20 g/L of hemoglobin), bilirubin (15-400 mg/L), and a fat emulsion (Intralipid 20%: 0.5-3 g/L). Maximal intensity (MaxInt) and velocity (Vel) were recorded in the basal state and in response to ADP 5 μmol/L and collagen 2 μg/mL. RBCH solution was treated with apyrase 0.1 U/mL.
resultsSpontaneous aggregation appeared above 0.6 g/L RBCH and significantly intensified with increased RBCH concentrations. The addition of apyrase to RBCH prevented spontaneous aggregation regardless of the RBCH concentration and led to reduced interindividual variability. In response to ADP and collagen, MaxInt and Vel significantly decreased as apyrase-treated RBCH concentrations increased. MaxInt and Vel in response to ADP or collagen were not affected by increasing concentrations of bilirubin. The presence of lipids significantly increases MaxInt in response to ADP or collagen starting at 0.5 g/L.
conclusionOur findings suggest that PA testing using the TA-8 V instrument is not significantly impacted by icterus and hyperlipidemia within the specified ranges in healthy individuals. However, it is crucial to reject grossly hemolysed samples (exceeding 0.6 g/L) to avoid interference with ADP released from red blood cells. Further research is needed to confirm these results in patients with platelet dysfunction.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.